DOCSLIB.ORG

Open Full Page

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Open Full Page 3IULTIPLE MYELOMA A REPORTOF FIVECASES ERNEST SCOTT, M.D., F. M. STANTON, M.D., AND MARY OLIVER, MA. (From the Department of Pathology, Ohio State University) In 1848 Sir Henry Bence-Jones aiid Sir James Watson pre- sented a paper entitled, “On a New substance Occurring in the Urine of a Patient with Mollitis-ossium,” a “substance” now known as the Bence-Jones bodies, frequeiitly found in the urine of patients with multiple myeloma. The clinical discussion of this same case mas presented in 1850 by McIntyre. In 1873 von Rustizky, in his histological studies of the disease, recognized its involvement of the bone marrow and gave it the name of multiple myeloma. IGililer, in 1889, ~lsopresented a clinical description of the disease and inasmuch as he, rather than McIntyre, has often been credited with the first clinical presentation, the term “Kahler ’s disease” is frequently encountered in the older litera- ture. In 1920 Wallgren reported 120 cases with histological verifica- tion. In 1928 Geschickter and Copeland (l), from the surgical pathological material of the Johns Hopkins Hospital, reported a series of 13 cases, together with a complete review of all available cases in the literature, making a total of 425 cases. Since the publication of this comprehensive article with its discussion of the clinical and structural characteristics of the disease, we have been able to collect from the more recent literature 30 cases of multiple myeloma. To these we add 5 cases from among about 4400 au- topsies in our own series. Grouped by years, the additional cases are : 1927 : Lewis (2), Meyeriling (3), Kleine (4) ; 1928: Battaglia (5), Hcilmann (6), Barr (7),Durman (8), Short iind Crawford (9) ; 1929: Hewitt (10) (5 cases), Stone (ll), Cappel1 (12) (2 cases), Rogers (13), Hub- bard and Case (14) ; 1930: Perla aiid Hutner (15) (2 cases), Cabot (16), Geschickter (17), Freund (18) ; 1931: Cabot (19), Porchownik (20), Jackson et a1 (21) (5 cases). ETIOLOGY Multiple myeloma is a disease of later life. Eighty per cent of all cases, according to Geschickter and Copeland, occur be- tween the ages of forty aiid seventy, with the peak of incidence at 682 MULTIPLE MYELOMA 683 fifty-fiveyears. These authors find but three histologically proved cases under thirty-five years of age; while in the more recent literature are reported 4 cases below thirty-five years (Durman, Hubbard and Case, Rogers, Cabot). The incidence is more than twice as great among males as females. Of the 35 more recent cases, 26 or ‘75 per cent were in males, 9 in females. Wallgren found 68 per cent males among 98 cases, and Geschickter and Copeland in their study of 425 cases, 70 per cent. The latter also itate that in the Johns Hopkins records they found multiple myeloma in 0.03 per cent of all malignancies. CLINICALFEATURES Pain.: Pain, rheumatic and often intermittent, is a frequent first symptom. It occurs most often in the lumbar and sacral regions, next in frequency over the ribs and sternum. Sudden onset of pain with tenderness in the lumbar or dorsal regions was found in all of the present series. The severity of the pain may subside for some months, only to return with the greatest intensity. In the later stages of the disease neurologic symptoms may ap- pear. Forty per cent of the cases report paraplegias and other neurologic disturbances due to compression of the cord (1). In cases 1 and 4 of our series there is record of complete paralysis from the waist down, almost total loss of sensation, and incon- tinence of urine and feces. Multiplicity: Multiple tumor involvement of the bone marrow is characteristic. The lesions vary in size from that of a pin-head to that of an orange. We found in the literature but two cases in which the lesion was single : (a) Geschickter ’s in 1930, a plasma- cell tumor occurring in the femur, and (b) Rogers’ in 1929, a plasma-cell myeloma of the femur with a history of successful amputation. The question of future multiple recurrence arises here, in consideration of the fact that Geschickter and Copeland’s case 10, with a history of amputation for myeloma of the femur, developed within two years multiple myeloma of several bones. In 90 per cent of the cases the ribs, sternum, clavicle or spine in some combination are involved (1). Forty per cent of these have in addition involvement either of the skull or of the ex- tremities about the shoulder or pelvic girdle. Subpleural nodules, as in case 1of our series, are not infrequent. Involving the spine alone, Cabot (16) (1930) reports a case of myeloma in the fourth dorsal vertebra. The lesions of multiple myeloma are to be distinguished from giant-cell sarcoma by the occurrence of the former in the shafts of the long bones, of the latter in their epiphyses. hfultiple myeloma is to be differentiated from endothelial myeloma (Ewing’s tumor) 684 ERNEST SCOTT, F. M. STANTON, AND MARY OLIVER by the frequent occurrence of the latter in childhood and by its existence as one nodule in a bone, in contrast to the adult-age incidence and multiple lesions of the former. Multiple myeloma, moreover, rarely infiltrates soft tissue. The roentgenogram reveals a characteristic, " punchecl-out '' appearance of tlic bonc-small (li scrcte arcas of rarefaction with ragged, moth-eaten outlines and little attempt at boiic repair. The vascularity is grcat and frequently produces a pulsation of tlie mass. -4s was markedly illustrated in case 5, a mere shell of bone may remain over the tumor mass, which can be very easily sliattcred giving rise to spoiitancous fracturcs on tlie slightest movement. Fmctuws : Fractures are very commoii. Among 425 cases tlicre were 62 per cent with pathologic fructnres (1). The most usual sites are in the trunk, first in the ribs, thcw in the clavicle and sternum. Several fractures may ocmr in the same bone. No other tumor of tlie bone or hone-marrow displays such a high pcr- centagc of fractures. Upon the basis of this clinical observation and the apparent bone-resorptive power of tlie tumor cell, Wil- liams (35) in 1932 advanced the theory that the myeloma tumor cell is derived from the osteoblast ratlicr than from tlie plasma cell or myeloblast. If this be the case, however, we should expect to find some attempt at bone repair, whicli we failed to see in any of our cases and which authors state is characteristically absent. Beuzce-Jones Bodies: Tlie clemonstration of the Bence-Jones bodies, a protein distiiict from albumin and globulin, depends 011 the appearance, between 45" C. and 60" C., of a white precipitate in the urine and its disappearance upon further heating to 90'- 100" C. During thc course of the disease its appearance may be iiitermittcnt. It w'as fo~indin the wine of 16 of the 30 cases u7c collected from the literature and iii oiic of our own associated with c~lironicnephritis. It was not tested for in three of onr cases. On the other hand, Bencc-Jones bodies are found in a number of otlicr diseases involving the bone marrow (Boggs :uid Guthrie, 22) such as osteomalacia, mysedcma with bone clianges, lymphatic leukemia, aiid carcinoma of tlie stomach with bone metastases. Some authors consider it an intermediary metabolic substance wliicli may be due to a toxin from the tumor. Pcrlzwcig, Delruc, aiid Gescliickter (23) found a liypcrproteinuria associated with multiple myeloma, which they explain as a systemic respoiisc to tlie foreign-body proteins prescnt in tlie Bence-Jones bodies. Perla and Hutiier (15) found in their studies an association of Hence-Jones proteinuria and arteriosclerotic nephritis. They cx- plain the variable occurrence of Bence-Jones bodies in tlie urine as dependent on the presence of kidney lesions which may mist in MULTIPLE MYELOMA 685 the older age groups independently of tlie myeloma. It is not yet certainly known wlietlier Rcnce-Jones proteins can pass through the normal kidney. Metastases: Metastases are said to be rare in multiple myeloma. Hemopoietic tissues, as tlic spleen, liver, and lymph glands, are the most frequent sites, but metastases have been reported in other organs. Several authors have taken the position tliat these arc not true metastases, but evidences of a systemic disease of the hemopoietic organs, as Syrnmers (24), Hoffman, Heilmann, Barr, Jackson et al. In the hlood vessels of many of the bone-marrow growths, however, and in tlie liver sinusoids and kicliiey capillaries of Case 4, free tumor cells were found. It is to be expected that, if the tumor cell is a derivative of licmopoietic tissue and multiple myeloma is, therefore, a specific tumor of the bone marrow and general hemopoietic tissues in which the plasma cell is the neo- plastic element, the neoplasm will display a predilection for the marrow rather tlian for the epipliyses of tlic bones and will occur in multiple foci in tlie same aiid other bones through clircct ex- tension in the vascular tissue and through metastases. In view of the occurrence of tumor cells in kidney capillaries aiid liver sinusoids as well as in the marrow blood vessels, it seems to us that genuine metastasis is uiidoubteclly one method of dissemina- tion, and that by this means and by direct extension the multiple occurrence of tliese growths can be explained. On the contrary, it cannot be denied that the theory of a generalized hemopoietic origin has as yet not been entirely disproved. Bow Defornzities: Skeletal deformities were found in GO per cent of the cases (1). They are chiefly confined to the thorax and rarely involve the extremities, in this respect differing from the deformities of Paget’s disease aiid osteomalacia.
Load more

Recommended publications
  • Cytology of Myeloma Cells
    J Clin Pathol: first published as 10.1136/jcp.29.10.916 on 1 October 1976. Downloaded from J. clin. Path., 1976, 29, 916-922 Cytology of myeloma cells F. G. J. HAYHOE AND ZOFIA NEUMAN1 From the Department of Haematological Medicine, Cambridge University SYNOPSIS A cytological, cytochemical, and cytometric study of plasma cells from 195 cases of multiple myeloma showed that, contrary to earlier reports, flaming cells, thesaurocytes, and intra- nuclear inclusions are not confined to IgA-secreting cases but are common also in IgG and Bence Jones varieties of myeloma. IgA-secreting cells are not larger, nor do they have a lower nuclear- cytoplasmic ratio than other myeloma cells. On average, for a given mass of tumour, Bence-Jones, IgG, and IgA varieties of myeloma produce amounts of paraprotein in the ratio 1 to 1 6 to 2-7. In 1961 Paraskevas et al reported a correlation the results of a larger scale survey carried out some between the morphological features of plasma cells years ago but previously unpublished. in myeloma and the type of immunoglobulin secreted. The cases studied included 12 with y1A Material and methods (f2A, IgA) myeloma, 30 with y (IgG) myeloma, and six myelomas without M protein (probably Bence The study was performed on bone marrow smearscopyright. Jones myelomas). Flaming cells, thesaurocytes, and from 200 consecutive patients newly entered into a intranuclear, PAS-positive inclusion bodies were comparative trial of treatments in myeloma, under found only in cases of IgA myeloma, and flaming the auspices of the Medical Research Council. Five cells especially were present in most cases and in patients were subsequently excluded as not confirmed high percentage in several.
    [Show full text]
  • Evidence-Based Practice Center Systematic Review Protocol
    Evidence-based Practice Center Systematic Review Protocol Project Title: Serum-Free Light Chain Analysis for the Diagnosis, Management, and Prognosis of Plasma Cell Dyscrasias I. Background and Objectives for the Systematic Review Plasma cell dyscrasias (PCDs) are a spectrum of disorders characterized by the expansion of a population of monoclonal bone-marrow plasma cells that produce monoclonal immunoglobulins.1 At the benign end of the spectrum is monoclonal gammopathy of undetermined significance (MGUS), where the plasma-cell clone usually does not expand. Multiple myeloma (MM) is a plasma cell disorder at the malignant end of the spectrum and is characterized by the neoplastic proliferation of a clone of plasma cells in the bone marrow with resulting end-organ damage, including skeletal destruction (lytic bone lesions), hypercalcemia, anemia, and renal insufficiency. Whereas monoclonal plasma cells generally secrete intact immunoglobulin, in about 20 percent of patients with MM these cells only produce light-chain monoclonal proteins (i.e., light-chain multiple myeloma [LCMM], formerly known as Bence Jones myeloma) and in 3 percent of patients they secrete neither light- nor heavy-chain monoclonal proteins that are detectable by immunofixation (i.e., nonsecretory multiple myeloma [NSMM]).1 In two-thirds of patients with NSMM, a monoclonal protein can be identified by the serum-free light chain (SFLC) assay. Patients with LCMM develop complications related to tissue deposition of light chains, including amyloidosis. Amyloid light-chain (AL) amyloidosis is the most common form of systemic amyloidosis seen in the United States and is characterized by a relatively stable, slow-growing plasma-cell clone that secretes light-chain proteins that form Table 1: Diagnostic criteria and clinical course of selected plasma cell dyscrasias (PCDs)2 Disorder Disease Definition Clinical Course Monoclonal gammopathy of .
    [Show full text]
  • Canine Multiple Myeloma
    Canine Multiple Myeloma Meredith Maczuzak, DVM; Kenneth S. Latimer, DVM, PhD; Paula M. Krimer, DVM, DVSc; and Perry J. Bain, DVM, PhD Class of 2003 (Maczuzak) and Department of Pathology (Latimer, Krimer, Bain), College of Veterinary Medicine, University of Georgia, Athens, GA 30602-7388 Introduction Multiple myeloma or plasma cell myeloma, is a neoplasm of well- differentiated B cell lymphocytes typically originating from the bone marrow. Neoplastic cells can metastasize widely, having a predilection for bone and resulting in osteolysis. The malignant transformation of a single B cell can secrete a homogenous immunoglobulin product known as paraprotein, which will mimic the structure of normal immunoglobulins. Overabundant production of paraprotein, consisting of any of the immunoglobulin classes, will appear as a sharp, well-defined peak or monoclonal gammopathy on serum electrophoresis. The most frequently encountered multiple myelomas secrete IgG or IgA paraproteins, however IgM myelomas (macroglobulinemia) have also been diagnosed in companion animals. Light chain disease is caused by plasma cell overproduction of the light chain segment of the immunoglobulin complex, consisting of either the lambda or kappa light chain. These proteins are referred to as Bence-Jones proteins and are the most commonly observed immunoglobulin fragments in the monoclonal gammopathies.2 There are rare instances where a malignant plasma cell neoplasm will be nonsecretory. These tumors occur in approximately 1% of all cases of multiple myeloma and are referred
    [Show full text]
  • Chapter 7: Hematologic Disorders and Kidney Disease
    Chapter 7: Hematologic Disorders and Kidney Disease Ala Abudayyeh, MD,* and Kevin Finkel, MD, FACP, FASN, FCCM*† *Division of General Internal Medicine, Section of Nephrology, University of Texas MD Anderson Cancer Center, Houston, Texas; and †UTHealth Science Center at Houston Medical School, Department of Medicine, Division of Renal Diseases and Hypertension, Houston, Texas MULIPLE MYELOMA chains precipitate with Tamm-Horsfall protein (THP) secreted by the thick ascending limb of the Pathogenesis loop of Henle and produce casts in the distal tubule. Multiple myeloma (MM) is a hematologic malig- Decreased GFR may increase the concentration of nancy involving the pathologic proliferation of light chains in the distal tubule and enhance the terminally differentiated plasma cells. It is the formation of casts. Therefore, hypercalcemia, vol- second most common hematologic malignancy ume depletion, diuretics, and nonsteroidal anti- behind non-Hodgkin lymphoma, with an annual inflammatory drugs can exacerbate renal injury. incidence of 4–7 cases per 100,000 in the United In some cases of AKI associated with MM, cast States. Clinical symptoms are due to osteolysis of formation is rare on renal biopsy. Instead, renal the bone, suppression of normal hematopoiesis, injury is attributed to the direct toxic effects of and the overproduction of monoclonal immuno- urinary free light chains (FLCs) on proximal tubule globulins that deposit in organ tissues. Clinical cells (5,6). After reabsorption, lysosomal degrada- symptoms include bone pain and fractures, anemia, tion of FLCs can activate the NF-kB pathway lead- infections, hypercalcemia, edema, heart failure, and ing to oxidative stress with an inflammatory renal disease. response, apoptosis, and fibrosis.
    [Show full text]
  • Intranuclear Inclusions in Myeloma Patient
    Published online: 2021-05-24 Letter to Editor Pathologist’s Feast: Intranuclear Inclusions in Myeloma Patient Sir, aspiration [Figure 2]. Plasma cells showed Dutcher body We present a case of a 36‑year‑old female admitted in bone marrow aspiration [Figure 3] as periodic acid– in hospital with complaints of pain in sacral region Schiff positive intranuclear inclusion [Figure 4]. The bone radiating toward right lower limb for 1 month. Laboratory marrow biopsy showed loss of normal architecture with examination revealed hemoglobin 8.1 g/dL, red blood packed marrow studded by plasma cells [Figure 5]. cell count – 2.61 × 109/mm3, white blood cell count Multiple myeloma account for 1% of all cancers and 16.16 × 103/mm3, and platelet count 299 × 109/mm3. The approximately 10% of all hematological malignancies.[1] The differential showed polymorphs – 74%, lymphocytes – 22%, eosinophils – 1%, and monocytes – 3%. Peripheral blood peak incidence is seventh decade, and it is quite rare, below smear showed rouleaux formation in red blood cells. The 40 years of age. The clinical and biological characteristics serum biochemistry showed blood urea – 54 mg/dl and of multiple myeloma in young patients are similar to those [2] creatinine – 3.8 mg/dl, angiotensin converting enzyme in elderly as in literature in studies by Usha et al. and [3] level – 64.25 U/L, and serum calcium – 13.3 mg/dl. Liver Bladé et al. The above case shows ditcher body inclusions function tests and serum electrolytes were normal and in plasma cells on bone marrow aspiration. HIV and HBsAg were nonreactive.
    [Show full text]
  • Successful Autologous Peripheral Blood Stem Cell Harvest and ­Transplantation After Splenectomy in a Patient with Multiple ­Myeloma with Hereditary Spherocytosis
    International Journal of Myeloma 8(3): 11–15, 2018 CASE REPORT ©Japanese Society of Myeloma Successful autologous peripheral blood stem cell harvest and transplantation after splenectomy in a patient with multiple myeloma with hereditary spherocytosis Daisuke FURUYA1,4, Rikio SUZUKI1,4, Jun AMAKI1, Daisuke OGIYA1, Hiromichi MURAYAMA1,2, Hidetsugu KAWAI1, Akifumi ICHIKI1,3, Sawako SHIRAIWA1, Shohei KAWAKAMI1, Kaito HARADA1, Yoshiaki OGAWA1, Hiroshi KAWADA1 and Kiyoshi ANDO1 Hereditary spherocytosis (HS) is the most common inherited red cell membrane disorder worldwide. We herein report a 58-year-old male HS patient with mild splenomegaly who developed symptomatic multiple myeloma (MM). Autologous stem cell transplantation (ASCT) was considered to be adopted against MM, although there was a possibility of splenic rupture following stem cell mobilization. Therefore, splenectomy was performed prior to stem cell harvest, and he was able to safely mobilize sufficient CD34+ cells with G-CSF and plerixafor and undergo ASCT. This case suggests that stem cell mobilization after splenectomy is safe and effective in HS patients complicated with malignancies. Key words: multiple myeloma, hereditary spherocytosis, splenectomy, autologous peripheral blood stem cell harvest Introduction Consolidation with melphalan-based HDT followed by ASCT is still the standard treatment option for transplant-eligible Multiple myeloma (MM) is characterized by clonal prolifera- patients with MM, leading to higher complete response rates tion of abnormal plasma cells in the bone marrow (BM) micro- and increased progression-free survival and overall survival environment, monoclonal protein in the blood and/or urine, compared with conventional chemotherapy regimens [2]. bone lesions, and immunodeficiency [1]. In recent years, the Importantly, the emergence of novel agent-based therapy introduction of high-dose chemotherapy (HDT) and autol- combined with ASCT has revolutionized MM therapy [2].
    [Show full text]
  • Clinical Hematology 1
    CLINICAL HEMATOLOGY 1 CLINICAL HEMATOLOGY Editor Gamal Abdul Hamid, MD,PhD Associate Professor Faculty of Medicine and Health Sciences University of Aden CLINICAL HEMATOLOGY 2 PREFACE Clinical Hematology, first edition is written specifically for medical students, the clinician and resident doctors in training and general practioner. It is a practical guide to the diagnosis and treatment of the most common disorders of red blood cells, white blood cells, hemostasis and blood transfusion medicine. Each disease state is discussed in terms of the pathophysiology, clinical and paraclinical features which support the diagnosis and differential diagnosis. We bring together facts, concepts, and protocols important for the practice of hematology. In addition this book is also supported with review questions and quizzes. G.A-H 2012 CLINICAL HEMATOLOGY 3 CONTENTS Preface 1. Hematopoiesis 7 2. Anemia 26 3. Iron Deficiency Anemia 32 4. Hemolytic Anemia 41 5. Sickle Cell Hemoglobinopathies 49 6. Thalassemia 57 7. Hereditary Hemolytic Anemia 63 8. Acquired Hemolytic Anemia 68 9. Macrocytic Anemia 75 10. Bone Marrow Failure, Panctopenia 87 11. Spleen 95 12. Acute Leukemia 99 13. Chronic Myeloproliferative Disorders 125 14. Chronic Lymphoproliferative Disorders 137 15. Malignant Lymphoma 147 16. Multiple Myeloma and Related Paraproteinemia 171 17. Hemorrhagic Diseases 179 18. Transfusion Medicine 201 19. Bone Marrow Transplantations 214 CLINICAL HEMATOLOGY 4 Appendices: I. Hematological Tests and Normal Values 221 II. CD Nomenclature for Leukocytes Antigen 226 III. Cytotoxic Drugs 228 IV. Drugs Used in Hematology 230 Glossary 232 Answers 246 Bibliography 247 CLINICAL HEMATOLOGY 5 CLINICAL HEMATOLOGY 6 HEMATOPOIESIS 1 All of the cells in the peripheral blood have finite life spans and thus must be renewed continuously.
    [Show full text]
  • © 2016 First Aid for the USMLE Step 1
    Index A Abscess, 442 vs. aspirin, in pediatric patients, 446 Achondroplasia, 426 Abacavir, 184 Absence seizures, 494 free radical injury and, 221 autosomal dominance of, 71 for HIV, 186 drug therapy for, 500 necrosis caused by, 252 chromosome associated with, 75 Abciximab, 214, 407 treatments for, 638 for osteoarthritis, 430 endochondral ossification in, 425 thrombogenesis and, 385 Absolute risk reduction (ARR), 34, for tension headaches, 494 AChR (acetylcholine receptor), 229 Abdominal aorta, 342 646 toxicity effects, 446 Acid-base physiology, 543 atherosclerosis in, 286, 645 Absorption disorders, anemia caused toxicity treatment for, 251 Acidemia, 543 bifurcation of, 609 by, 388 Acetazolamide, 254, 557 diuretic effect on, 558 498 92 Abdominal aortic aneurysm, 286 Abuse for glaucoma, Acidic amino acids, metabolic acidosis caused by, 543 Acidosis, 543 Abdominal colic confidentiality exceptions and, 41 in nephron physiology, 537 contractility in, 267 lead poisoning as cause, 389 dependent personality disorder for pseudotumor cerebri, 471 hyperkalemia caused by, 542 Abdominal distension and, 519 site of action, 556 Acid phosphatase, in neutrophils, 378 duodenal atresia as cause, 338 Acalculia, 464 Acetoacetate, metabolism of, 102 Acid reflux Abdominal pain Acamprosate Acetone breath, in diabetic esophageal strictures and, 354 Budd-Chiari syndrome as for alcoholism, 523, 638 ketoacidosis, 331 esophagitis and, 354 cause, 368, 630 diarrhea caused by, 252 Acetylation, 57 H blockers for, 374 cilostazol/dipyridamole as Acanthocytes, 386 2 Acetylcholine
    [Show full text]
  • Myeloma for Diagnosticians
    Myeloma for Diagnosticians Dr Mamta Garg Consultant Haematologist What is Myeloma? Malignant disorder of plasma cells • an excess of abnormal plasma cells >10% • paraprotein in the serum and/or urine • End organ affection CRAB, SLiM CRAB Diagnosis: Paraprotein or M protein SPEP CRAB and now “Slim CRAB” • Myeloma defining events or Evidence of end organ damage that can be attributed to the underlying plasma cell proliferative disorder, specifically: – C: Hypercalcaemia: serum calcium >0·25 mmol/L higher than the upper limit of normal or >2·75 mmol/L R: Renal insufficiency – R: Creatinine clearance <40 mL per min or serum creatinine >177 μmol/L (>2 mg/dL) – A: Anaemia: Hb >20 g/L below usual Hb, or a Hb <100 g/L – B: Bone lesions: one or more osteolytic lesions on XR, CT or PET-CT • Any one or more of the following biomarkers of malignancy: – S (M-spike) : Clonal bone marrow plasma cell percentage* ≥60% – Li: Involved:uninvolved serum free light chain ratio≥100 (or <0.01) – M: >1 focal lesions on MRI studies of 1 cm in size Rajkumar et al. Lancet Oncol. 2014 Nov;15(12):e538-48 Asymptomatic/Smouldering Myeloma • M protein present in serum and/or urine • Plasma cells >10% in the marrow • No CRABs • It carries a higher risk of progression to frank multiple myeloma (10% per year the first 5 years) compared with MGUS ISS, now Revised ISS or R-ISS LDH and FISH analysis on BM sample mandatory ISS STAGE CRITERIA RISK CRITERIA I B2M <3.5 Albumin >35 Normal Normal Serum LDH <upper limit of normal II B2M >3.5 but <5.5 or Albumin <35 High High serum
    [Show full text]
  • Pathology Course
    Pathology Course Kindly Sponsored by: Edited by: Michelle Kunc, Jhia Teh, Sally Barker and Yvonne Tsitsiou 1 Introduction The Medical Education Society (MedED) was established in 2004 by three students who were keen to develop schemes whereby senior students tutor younger ones - ‘peer-to- peer’ learning. It was decided that teaching would be outside the formal curriculum and the topics covered would reflect learning needs identified by members of the society and student body. This year we have coordinated PACES and Pathology revision courses, which are being delivered by past ICSM students. We hope you enjoy our Year 5 events and find their content useful for your revision. We would like to thank all the doctors involved in the production of this guide for their support and for taking time out of the schedules to come back and teach us. We would also like to thank the previous MedED guide editors: • 2016-2017: Daniel Campioni-Norman, Rhys Smith, Helen-Cara Younan and Rebekah Judge • 2017-2018: Charlie Caird, Stephanie EzeKwe, Mohammad Fallaha, Samyukta Sundar • 2018-2019: Sophia von Widekind, Lasith Ranasinghe, Daniel Huddart, Alex Huddart If you have any questions please contact us at [email protected]. Please note: MedED does not represent the ICSM Faculty or Student Union. This guide has been produced by students and the Pathology Course lecturers. We have made every effort to ensure that the following information is accurate and reliable. However, this guide should not be used to replace formal ICSM teaching and education
    [Show full text]
  • View the 2019 Index
    Index A Abnormal uterine bleeding (AUB), heart failure, 311 Achondroplasia, 454 A-a gradient 618, 619 hypertension, 319 chromosome disorder, 64 in elderly, 654 adenomyosis, 634 naming convention for, 253 endochondral ossification in, 450 with hypoxemia, 654, 655 anemia with, 410 preload/afterload effects, 282 inheritance, 60 restrictive lung disease, 661 Asherman syndrome, 634 teratogenicity, 600 AChR (acetylcholine receptor), 229 Abacavir, 201, 203 leiomyoma (fibroid), 634 Acetaldehyde, 72 Acid-base physiology, 580 Abciximab, 122 polyps (endometrial), 634 Acetaldehyde dehydrogenase, 70, 72 Acidemia, 580 Glycoprotein IIb/IIIa inhibitors, thecoma, 632 Acetaminophen, 474 diuretic effect on, 595 429 ABO blood classification, 397 vs. aspirin for pediatric patients, 474 Acid-fast oocysts, 177 thrombogenesis and, 403 newborn hemolysis, 397 free radical injury and, 210 Acid-fast organisms, 125, 140, 155 Abdominal aorta, 357 Abruptio placentae, 626 hepatic necrosis from, 249 Acidic amino acids, 81 atherosclerosis in, 305, 687 cocaine use, 600 N-acetylcysteine for overdose, 671 Acid maltase, 86 bifurcation of, 649 preeclampsia, 629 for osteoarthritis, 458 Acidosis, 578, 580 Abdominal aortic aneurysm, 306 Abscess, 470 toxicity effects, 474 contractility in, 282 Abdominal colic acute inflammation and, 215 toxicity treatment for, 247 hyperkalemia with, 578 lead poisoning, 411 lung, 670 Acetazolamide, 252, 539, 594 Acid phosphatase in neutrophils, 398 Abdominal pain Absence seizures idiopathic intracranial Acid reflux bacterial peritonitis, 384 characteristics
    [Show full text]
  • Bence Jones Proteins: Nature, Metabolism, Detection and Significance MICHAEL J
    ANNALS OF CLINICAL AND LABORATORY SCIENCE, Vol. 6, No. 1 Copyright @ 1976, Institute for Clinical Science Bence Jones Proteins: Nature, Metabolism, Detection and Significance MICHAEL J. DEEGAN, M.D. Clinical Immunology Laboratory, Department of Pathology, The University of Michigan Ann Arbor, MI 48104 ABSTRACT The nature of Bence Jones proteins is developed by a review of the pertinent literature. This is followed by a discussion of their metabolism and catabolism under normal and abnormal clinical conditions. Various methods for the detection of Bence Jones proteins are critically reviewed and the significance of these pro­ teins in various disorders is assessed. Nature more than a century after the initial descrip­ tion. In 1845 Henry Bence Jones, a physician The modern era of Bence Jones (BJ) pro­ and chemical pathologist at St. George’s tein analysis began with a report by Hospital in London, received a specimen of Edelman and Gaily16 that BJ proteins shared urine from Dr. Thomas Watson. The urine extensive antigenic cross-reactivity with was from a patient with an illness now myeloma proteins and normal gamma glob­ known to be multiple myeloma. Accom­ ulins. Putnam35 compared peptide maps of panying the specimen was a note the text of pooled human gamma globulin, seven which is reproduced here.11 purified pathologic globulins and eight BJ “The tube contains urine of very high proteins. On the basis of these studies, he specific gravity. When boiled it becomes concluded that there were two types of BJ highly opaque. On the addition of nitric acid protein and that they represented incom­ it effervesces, assumes a reddish hue and be­ plete or aberrant polypeptide chains of comes quite clear; but as it cools assumes the normal gamma globulin.
    [Show full text]